Recalculation of warrants in series TO3, TO4 and TO5 due to Brighter’s benefit issue
In clarification of the announcement on the benefit issue in Brighter AB (publ) ("Brighter" or "the Company") on November 18, the Company hereby informs of the principles for recalculation in accordance with the applicable terms for warrants in series TO3, TO4 and TO5, listed on Nasdaq First North Growth Market.
Principles for recalculation of warrants in series TO3
According to the terms for warrants in the TO3 series, the subscription price shall be recalculated in such a way that the new subscription price corresponds to the subscription price in the benefit issue. This means that after recalculation, 1 warrant in the TO3 series will still give the right to subscribe for 1 new share in Brighter, but at a recalculated subscription price of SEK 2 per share.
Prior to recalculation, 1 subscription option in series TO3 gives the right to subscribe 1 new share in Brighter at a subscription price of SEK 4 per share.
The subscription period in series TO3 is 10 - 24 April 2020.
Principles for recalculation of warrants in series TO4
According to the terms for warrants in the TO4 series, the subscription price shall be recalculated in such a way that the new subscription price corresponds to the subscription price in the benefit issue. This means that after recalculation, 1 warrant in the TO4 series will still give the right to subscribe for 1 new share in Brighter, but at a recalculated subscription price of SEK 2 per share.
Prior to recalculation, 1 warrant in series TO4 gives the right to subscribe 1 new share in Brighter at a subscription price of SEK 6.01 per share.
The subscription periods in series TO4 are
- 22 february – 8 march 2020
- 25 august – 8 september 2020
Principles for recalculation of warrants in series TO5
According to the terms for warrants in the TO5 series, the benefit issue means that the number of shares that a warrant entitle to subscribe for in Brighter and the subscription price when subscribing for a share shall be recalculated. Such recalculation will take place after the completion of the rights issue, since one parameter in the recalculation is the average price of the share during the subscription period, which is 13 December 2019 - 3 January 2020.
Prior to recalculation, 1 warrant in series TO5 gives the right to subscribe 1 new share in Brighter at a subscription price of SEK 10.56 per share.
The subscription periods in series TO5 are
- 21 November – 12 December, 2019
- 22 May – 5 June, 2020
- 20 November – 4 December, 2020
- 21 May – June 4, 2021
- 22 November – 6 December, 2021
- 23 May – 6 June, 2022
- 21 November – 5 December, 2022
- 23 May – 5 June, 2023
Shares subscribed for under the TO5 warrant series prior to the record date in the ongoing benefit issue (which is December 12, 2019) will not be received in time to entitle the holder to participate in the rights issue, which means that such subscription will be managed in accordance with the recalculated terms, after recalculation according to the warrant terms.
Complete terms for the warrants
Complete terms for warrant series TO3, TO4 and TO5 can be found on Brighter's website, https://brighter.se/investors/financing-home/warrants.
About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – improving quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. https://brighter.se/
For further information, please contact:
Henrik Norström, CEO
Phone: +46 733 40 30 45
Email: henrik.norstrom@brighter.se
Ann Zetterberg, CFO
Phone: +46 708 37 21 23
E-mail: ann.zetterberg@brighter.se
About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – improving quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. https://brighter.se/
The Company's shares are listed on Nasdaq First North Growth Market/BRIG. Brighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 10, adviser@eminova.se, www.eminova.se.